LeMaitre Vascular provides medical devices and human tissue cryopreservation services for the treatment of peripheral vascular disease, end-stage renal disease, and to a lesser extent cardiovascular disease. Co.'s portfolio of devices consists of products that are used in arteries and veins. Co.'s product offerings include a suite of biologic products, which include the XenoSure patch (bovine pericardium), CardioCel and VascuCel patches (bovine pericardium), ProCol graft (bovine mesenteric vein), Artegraft (bovine carotid artery), Omniflow II biosynthetic graft (ovine tissue and synthetic mesh) and the RestoreFlow Allograft cryopreserved graft (human cadaver tissue). We show 56 historical shares outstanding datapoints in our LMAT shares outstanding history coverage, used to compute LMAT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing LMAT market cap history over the course of time is important for investors
interested in comparing LMAT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of LMAT versus a peer is one thing; comparing
LMAT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like LMAT can fluctuate over the course of history.
With this page we aim to empower investors researching LMAT by allowing them to research the LMAT market cap history. |
Free LMAT Email Alerts:
Video: The Importance of Market Cap
